Incyte Corp - Company Profile

Powered by

All the data and insights you need on Incyte Corp in one report.

$395 $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date Incyte Corp Strategy Report

  • Understand Incyte Corp position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Incyte Corp: Overview

Select Item

Related keylists

Incyte Corp (Incyte) is a biopharmaceutical company, which discovers, develops and commercializes proprietary cancer therapeutics. The company’s lead product, Jakafi (ruxolitinib) is marketed in the US for the treatment of patients with high-risk myelofibrosis; and polycythemia vera who are intolerant to hydroxyurea. The company distributes Jakafi through a network of specialty pharmacy providers and wholesalers. In collaboration with Incyte, Novartis International Pharmaceutical Ltd (Novartis) develops and commercializes ruxolitinib outside the US for hematologic and cancer indications under the name Jakavi. The company’s pipeline portfolio encompasses drugs for the treatment of lung cancer, graft versus host disease, b-cell malignancies, solid tumors, non-small cell lung cancer, glioblastoma, liver cancer, and advanced malignancies. Incyte is headquartered in Wilmington, Delaware, the US.

 Gain a 360-degree view of Incyte Corp and make more informed decisions for your business Gain a 360-degree view of Incyte Corp and make more informed decisions for your business Find out more
Headquarters United States of America
Address 1801 Augustine Cut-Off, Wilmington, Delaware, 19803
Website www.incyte.com
Telephone 1 302 4986700
No of Employees 2,324
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange INCY (NASD)
Revenue (2022) $3.4B 13.7% (2022 vs 2021)
EPS XYZ
Net Income (2022) XYZ -64.1% (2022 vs 2021)
Market Cap* $12.4B
Net Profit Margin (2022) XYZ -68.4% (2022 vs 2021)
* As of and is in US$
View Incyte Corp financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Incyte Corp premium industry data and analytics

580+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Incyte Corp’s relevant decision makers and contact details.

520+

Catalyst Calendar

Proactively evaluate Incyte Corp’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

460+

Clinical Trials

Determine Incyte Corp go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

90+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

50+

Pipeline Drugs

Identify which of Incyte Corp’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

17+

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

9

Sales & Consensus Forecasts

Understand the current and future drug revenue for Incyte Corp and assess market opportunity for new entrants with patient population 8-year forecasts.

6

Marketed Drugs

Understand Incyte Corp’s commercialized product portfolio to stay one step ahead of the market.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Incyte Corp’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Brands
Ruxolitinib Jakavi
Ponatinib Jakafi
Capmatinib Iclusig
XYZ XYZ
XYZ XYZ
XYZ XYZ
Understand Incyte Corp portfolio and identify potential areas for collaboration Understand Incyte Corp portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2023 Contracts/Agreements In September, the company entered into a collaboration with AbCellera to discover and develop therapeutic antibodies in oncology.
2023 Contracts/Agreements In July, the company and Replimune Group entered into a clinical trial collaboration and supply agreement to study RP1, Replimune’s lead product candidate in combination with INCB9928.
2023 Regulatory Approval In April, the company received marketing authorization from the European Commission for Opzelura (ruxolitinib) cream 15mg/g for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters Incyte Corp F. Hoffmann-La Roche Ltd Merck & Co Inc Gilead Sciences Inc Amgen Inc
Headquarters United States of America Switzerland United States of America United States of America United States of America
City Wilmington Basel Kenilworth Foster City Thousand Oaks
State/Province Delaware - New Jersey California California
No. of Employees 2,324 103,613 69,000 17,000 25,200
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Herve Hoppenot President; Chief Executive Officer; Chairman Executive Board 2014 63
Christiana Stamoulis Chief Financial Officer; Executive Vice President Senior Management 2019 52
Steven H. Stein, M.D. Executive Vice President; Chief Medical Officer Senior Management 2015 56
Dashyant Dhanak, Ph.D. Executive Vice President; Chief Scientific Officer Senior Management 2018 62
Pablo J. Cagnoni, M.D Head - Research and Development; President Senior Management 2023 -
Non Dignissim Eros Proin vel Convallis 2023 XY
Non Dignissim Eros Proin vel Convallis 2023 XY
Non Dignissim Eros Proin vel Convallis 2023 XY
Gain insight into Incyte Corp key executives to enhance your sales strategy Gain insight into Incyte Corp key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward